S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The gold catalyst we've waited for (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The gold catalyst we've waited for (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The gold catalyst we've waited for (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The gold catalyst we've waited for (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Positive News SentimentPositive News
NASDAQ:ZLAB

Zai Lab (ZLAB) Stock Forecast, Price & News

$24.31
+0.31 (+1.29%)
(As of 09/29/2023 ET)
Compare
Today's Range
$24.15
▼
$24.79
50-Day Range
$22.72
▼
$31.49
52-Week Range
$20.98
▼
$49.81
Volume
288,160 shs
Average Volume
366,223 shs
Market Capitalization
$2.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Zai Lab MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
241.8% Upside
$83.10 Price Target
Short Interest
Bearish
3.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.75) to ($2.70) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

700th out of 972 stocks

Pharmaceutical Preparations Industry

325th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

ZLAB stock logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Price History

ZLAB Stock News Headlines

September 18, 2023 | finance.yahoo.com
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
September 7, 2023 | seekingalpha.com
Zai Lab Stock: De-Risking Through Market Tapping
October 1, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 5, 2023 | msn.com
Rebel's Edge - September 5: $ABNB, $MANU, $ZLAB, and Royce Lewis hits 3 Grand-Slams In 8 Games
September 5, 2023 | markets.businessinsider.com
Pre-market Movers: HSDT, UPTD, ADTX, RENB, MLGO…
September 5, 2023 | msn.com
Zai Lab (NASDAQ:ZLAB) Soars 12% on Breakthrough Therapy Designation for Repotrectinib in China
August 31, 2023 | finance.yahoo.com
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
August 30, 2023 | finance.yahoo.com
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
October 1, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
August 10, 2023 | markets.businessinsider.com
Zai Lab (ZLAB) Receives a Buy from Bank of America Securities
August 8, 2023 | markets.businessinsider.com
Analysts Offer Insights on Technology Companies: Zai Lab (ZLAB) and Kratos Defense (KTOS)
August 8, 2023 | seekingalpha.com
Zai Lab GAAP EPS of -$1.25 misses by $0.50, revenue of $68.86M misses by $1.81M
August 7, 2023 | finance.yahoo.com
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
August 7, 2023 | finance.yahoo.com
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
August 3, 2023 | msn.com
Zai Lab Limited - ADR (ZLAB) Price Target Decreased by 5.82% to 34.24
July 27, 2023 | seekingalpha.com
Zai Lab: LUNAR Trial Paves Way For New Therapies
July 20, 2023 | finance.yahoo.com
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
July 19, 2023 | finance.yahoo.com
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
July 17, 2023 | msn.com
Argenx, Zai Lab Soar on Promising Data in CIDP
July 17, 2023 | markets.businessinsider.com
Jefferies Reaffirms Their Buy Rating on Zai Lab (ZLAB)
July 17, 2023 | finance.yahoo.com
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 14, 2023 | finance.yahoo.com
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
July 12, 2023 | seekingalpha.com
Zai Lab: Encouraging Developments Amid Ever-Present Geopolitical Risk
July 10, 2023 | finance.yahoo.com
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
July 6, 2023 | finance.yahoo.com
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
July 6, 2023 | finance.yahoo.com
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
July 1, 2023 | benzinga.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLAB
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings
8/07/2023
Today
9/30/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
CUSIP
N/A
CIK
1704292
Web
www.zailaboratory.com
Phone
862161632588
Fax
86-21-6163-2570
Employees
2,036
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$83.10
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$62.50
Forecasted Upside/Downside
+241.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-443,290,000.00
Net Margins
-156.07%
Pretax Margin
-156.07%
Return on Equity
-38.48%
Return on Assets
-32.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.63
Quick Ratio
7.36

Sales & Book Value

Annual Sales
$215.04 million
Price / Sales
11.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.68 per share
Price / Book
2.28

Miscellaneous

Outstanding Shares
98,840,000
Free Float
93,670,000
Market Cap
$2.40 billion
Optionable
Optionable
Beta
1.12
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Ying Du Ph.D. (Age 57)
    Founder, Chairperson & CEO
    Comp: $1.67M
  • Mr. Joshua L. Smiley (Age 53)
    Pres & COO
    Comp: $647.11k
  • Dr. Rafael G. Amado M.D. (Age 59)
    Pres and Head of Global Oncology R&D
    Comp: $477k
  • Dr. Harald Reinhart M.D. (Age 71)
    Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
    Comp: $923.33k
  • Dr. Yajing Chen Ph.D.
    Chief Financial Officer
  • Dr. Peter Huang Ph.D.
    Chief Scientific Officer
  • Mr. Frazor Titus Edmondson III (Age 57)
    J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Ann E. Beasley J.D.
    Chief Compliance Officer
  • Dr. Ning Xu M.D. (Age 58)
    Exec. VP & Head of Clinical Operations
  • Dr. Jonathan J. Wang MBA (Age 41)
    Ph.D., Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.

What is Zai Lab's stock price forecast for 2023?

3 brokers have issued twelve-month target prices for Zai Lab's stock. Their ZLAB share price forecasts range from $62.50 to $130.00. On average, they anticipate the company's share price to reach $83.10 in the next year. This suggests a possible upside of 241.8% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 at the beginning of the year. Since then, ZLAB stock has decreased by 20.8% and is now trading at $24.31.
View the best growth stocks for 2023 here.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ZLAB earnings forecast.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) released its quarterly earnings results on Monday, August, 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.51. The company earned $68.86 million during the quarter, compared to analyst estimates of $71.40 million. Zai Lab had a negative trailing twelve-month return on equity of 38.48% and a negative net margin of 156.07%.

What ETFs hold Zai Lab's stock?

ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Fidelity Disruptive Medicine ETF (FMED) and Invesco Golden Dragon China ETF (PGJ) and

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab issued an update on its second quarter earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of ($1.25) for the period, compared to the consensus EPS estimate of ($0.79). The company issued revenue guidance of $68.9, compared to the consensus revenue estimate of $70.48 million.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $24.31.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $2.40 billion and generates $215.04 million in revenue each year. The company earns $-443,290,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis.

How many employees does Zai Lab have?

The company employs 2,036 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -